Analysis of the Immune Checkpoint V-Domain Ig-Containing Suppressor of T-cell Activation (VISTA) in Endometrial Cancer

Researchers investigated VISTA expression and determine its associations with clinicopathological features, molecular subtypes, programmed cell death-ligand 1 expression, CD8+ T-cell count, and survival in a cohort of 839 patients with endometrial cancer.